Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

GHK-Cu is discussed for its potential anti-aging and healing properties, with some users considering its effects on hair growth. One user mentions using Folligen Spray and topical finasteride, noting improved healing but uncertain hair growth results.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

The user experienced temporary peach fuzz growth using a product with procapil and later tried minoxidil and finasteride without significant results. Their boyfriend has used minoxidil and finasteride consistently for over five years with sparse hair improvement.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

GLA may help with hair loss due to its anti-inflammatory properties and 5ar enzyme inhibition. It's considered potentially more important than biotin, especially for those already using finasteride and dutasteride.

An 18-year-old male with hair loss is considering starting finasteride but is concerned about potential side effects like gynecomastia due to his prolactin levels. He seeks guidance on whether his bloodwork indicates it's safe to begin treatment.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

The conversation discusses concerns about using a high concentration of 1% topical finasteride for hairline balding, with some users suggesting starting with a lower dose. It also mentions the use of GHK-CU peptide and the importance of considering the formulation to avoid excessive absorption.

Aminexil/Kopexil may help reduce hair loss by addressing perifollicular fibrosis in androgenetic alopecia, but it lacks the extensive clinical backing of finasteride and minoxidil. Some users find it effective, but availability and cost are issues, especially in the US where it's not FDA-approved.

Taking zinc may reduce side effects of finasteride, such as gyno, by preventing testosterone from converting to estrogen. Some users report improved symptoms with zinc, but excessive intake can cause issues like copper deficiency or stomach problems.

Switching from propylene glycol to glycerin in topical finasteride may reduce systemic absorption and side effects while maintaining local scalp DHT suppression. Concerns exist about glycerin's ability to deliver the full dose to hair follicles.

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.

The conversation discusses a user experiencing gynecomastia after taking finasteride and using zinc supplements to alleviate symptoms. Other users suggest stopping finasteride and consider alternatives like oral minoxidil.

The user has been using topical finasteride since October without improvement and is considering adding a caffeine product with dimethylglycine. Another user suggests caffeine is more promising and advises consulting a dermatologist about the lack of progress with finasteride.

The user expresses positivity about managing hair loss and celebrates good hair days. They mention using finasteride (Propecia) as part of their treatment.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

The conversation is about a user offering free unused Eucapil after switching to finasteride for hair loss treatment. The user did not use Eucapil and is willing to give it away locally or ship it if costs are covered.

A satirical post humorously discusses a fictional hair regrowth drug called PP405, with users joking about its effectiveness and bizarre presentation. The conversation includes humorous reactions and references to the absurdity of the content.

Hair loss may be linked to the GPR133 receptor, independent of the androgen receptor pathway. Treatments like finasteride, dutasteride, minoxidil, RU58841, and KX-826 show varying results, with hair loss persisting due to high testosterone and GPR133's role.

The user experienced good hair regrowth using natural methods and mechanical stimulation but decided to add finasteride to their regimen for better results. They are optimistic about further regrowth and plan to update on the effects of finasteride, noting no significant side effects so far.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

A user shared their experience with hair loss, using finasteride and minoxidil, and eventually undergoing a hair transplant of 1800 grafts. They regret not starting finasteride earlier and mention that despite the transplant, their scalp is still visible under strong light.

David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.

Applying Epidermal Growth Factor (EGF) topically may improve skin and potentially promote scalp health and hair growth, especially after microneedling. The user shares their positive experience with EGF and provides a product link.

The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

Using DIM and Calcium D-Glucarate to reduce finasteride side effects. Discussion includes dosage, brand, and product effectiveness.

Topical finasteride can reduce scalp DHT as effectively as oral finasteride with fewer systemic effects, but availability is limited. Some users make their own solutions due to limited access.